Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while Vanguard Information Technology Index Fund ETF trades at $121.68. Which is the better fit depends on your goals.
| ABEO | VGT | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | — |
52-Week High | $7.45 | $125.77 |
52-Week Low | $4.17 | $83.59 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
VGT trades at $121.35, up 0.91% today, with a bullish technical outlook supported by moving averages but neutral oscillators. The ETF's pure-play technology focus, driven by AI infrastructure exposure, has attracted significant institutional buying, as seen in recent SEC filings. Recent news highlights strong performance relative to broader tech ETFs, with key holdings like Microsoft and Nvidia fueling gains.
Outlook remains positive due to AI-driven capital expenditure trends, though concentration risk in top holdings and potential sector volatility pose challenges. The ETF's low-cost structure and momentum position it for continued growth, but investors should monitor semiconductor cyclicality and broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
